IGI Laboratories submits third ANDA in 2014 to FDA

IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its third abbreviated new drug application (ANDA) in 2014 to the U.S. Food and Drug Administration (FDA), which brings the Company's total number of ANDA submissions to sixteen, with fourteen now pending at the FDA.

Jason Grenfell-Gardner, President and CEO of the Company, commented, "We now have fourteen ANDAs pending approval and on file with the FDA. Our 2014 goal of at least ten ANDA submissions remains on track. This is our second submission this month, and we plan to add to our pending submissions throughout this week. We believe our current pipeline of submissions pending approval by the FDA has a combined addressable market of over $395 million based on recent data from IMS Health."

Source:

IGI Laboratories, Inc.

Posted in: Pharmaceutical News

Tags: , ,

Advertisement

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Addressing unmet needs in prostate cancer